AU2001296805A1 - Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products - Google Patents

Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

Info

Publication number
AU2001296805A1
AU2001296805A1 AU2001296805A AU9680501A AU2001296805A1 AU 2001296805 A1 AU2001296805 A1 AU 2001296805A1 AU 2001296805 A AU2001296805 A AU 2001296805A AU 9680501 A AU9680501 A AU 9680501A AU 2001296805 A1 AU2001296805 A1 AU 2001296805A1
Authority
AU
Australia
Prior art keywords
metabolic product
cell
chimeric protein
ligand
protein comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296805A
Other languages
English (en)
Inventor
Frank Mccormick
Osamu Tetsu
Kenichi Wakita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2001296805A1 publication Critical patent/AU2001296805A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AU2001296805A 2000-10-13 2001-10-09 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products Abandoned AU2001296805A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/687,593 US6787321B1 (en) 2000-10-13 2000-10-13 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
US09/687,593 2000-10-13
PCT/US2001/031745 WO2002031201A2 (en) 2000-10-13 2001-10-09 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

Publications (1)

Publication Number Publication Date
AU2001296805A1 true AU2001296805A1 (en) 2002-04-22

Family

ID=24761035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296805A Abandoned AU2001296805A1 (en) 2000-10-13 2001-10-09 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

Country Status (7)

Country Link
US (2) US6787321B1 (enExample)
EP (1) EP1327003B1 (enExample)
JP (1) JP2004511237A (enExample)
AT (1) ATE520788T1 (enExample)
AU (1) AU2001296805A1 (enExample)
CA (1) CA2424317A1 (enExample)
WO (1) WO2002031201A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1573058T3 (da) * 2002-12-18 2012-01-16 Chromagenics Bv Fremgangsmåde til forbedring af proteinproduktion
BRPI0610821A2 (pt) * 2005-05-19 2010-07-27 Wyeth Corp método de identificação de compostos que modulam a interação de receptor de androgênio com beta-catenina
US20100099096A1 (en) * 2007-02-28 2010-04-22 The Brigham And Women's Hospital, Inc. Compositions and Methods for Identifying Factors Affecting Protein Stability
US20100197767A1 (en) * 2007-07-11 2010-08-05 Lior Nissim Nucleic acid construct systems capable of daignosing or treating a cell state
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
GB2584211B (en) * 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions
JP7773376B2 (ja) 2019-05-15 2025-11-19 シンセックス， インコーポレイテッド タンパク質の選択的分解

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370813A3 (en) 1988-11-25 1991-06-19 Exemplar Corporation Rapid screening mutagenesis and teratogenesis assay
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
FR2734567B1 (fr) 1995-05-26 1997-08-08 Commissariat Energie Atomique Proteines chimeriques activant la transcription par la polymerase iii, leur utilisation pour la detection et l'analyse des interactions entre proteines, et genes codant pour lesdites proteines
USH1892H (en) 1995-07-27 2000-10-03 Pharmacia And Upjohn Company High volume nutrient based yeast two-hybrid assay for the identification of specific protein:protein interacting inhibitors
US5948620A (en) 1996-08-05 1999-09-07 Amersham International Plc Reverse two-hybrid system employing post-translation signal modulation
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
ATE289353T1 (de) 1996-12-11 2005-03-15 Bristol Myers Squibb Co Prokaryotisches zwei-hybrid system
US5851775A (en) * 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
US6242253B1 (en) * 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same

Also Published As

Publication number Publication date
ATE520788T1 (de) 2011-09-15
WO2002031201A2 (en) 2002-04-18
EP1327003B1 (en) 2011-08-17
EP1327003A2 (en) 2003-07-16
US6787321B1 (en) 2004-09-07
CA2424317A1 (en) 2002-04-18
US7358086B2 (en) 2008-04-15
JP2004511237A (ja) 2004-04-15
US20040265791A1 (en) 2004-12-30
WO2002031201A3 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
Comer et al. O-GlcNAc and the control of gene expression
Perry et al. Anchoring of surface proteins to the cell wall of Staphylococcus aureus: III. Lipid II is an in vivo peptidoglycan substrate for sortase-catalyzed surface protein anchoring
Barbu et al. β-Neurexin is a ligand for the Staphylococcus aureus MSCRAMM SdrC
WO2003027266A3 (en) Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
EP0921395A3 (en) Assays for measurement of protein fragments in biological media
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
WO2003042402A3 (en) Agents that modulate immune cell activation and methods of use thereof
NZ504114A (en) Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability
HK1040745A1 (zh) 胞質磷脂酶a2的晶體結構以及用其來鑒定激動劑和拮抗劑的方法
WO2008060483A3 (en) Protein-protein interaction biosensors and methods of use thereof
WO2001077687A3 (en) Prion-binding peptidic ligands and methods of using same
WO2000031124A3 (en) Peptides that modulate the interaction of b class ephrins and pdz domains
ATE301188T1 (de) Reprimiertes trans-aktivatorsystem zur charakterisierung von protein-protein interaktionen
WO1999057149A3 (en) Compounds and methods for modulating nonclassical cadherin-mediated functions
WO2003000856A3 (en) In vitro protein interaction detection systems
AU5203199A (en) Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
DE69826888D1 (de) Bakterielles multi-hybrid system und anwendungen dafür
AU2002239229A1 (en) Receptor for b. anthracis toxin
WO2002031201A3 (en) Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
WO2001072956A3 (en) Compounds and methods for modulating desmosomal cadherin-mediated functions
AU2002250462A1 (en) Efficient methods for isolating functional g-protein coupled receptors and identifying active effectors and efficient methods to isolate proteins involved in olfaction and efficient methods to isolate and identifying active effectors
WO2010039748A3 (en) Botulinum neurotoxin e receptors and uses thereof
WO1998049292A3 (fr) Polypeptides associes a des recepteurs activateurs et leurs applications biologiques
WO2002061046A3 (en) Novel nucleic acid and polypeptide molecules